Waterloo Capital L.P. Sells 236 Shares of CVS Health Co. (NYSE:CVS)

Waterloo Capital L.P. trimmed its position in shares of CVS Health Co. (NYSE:CVS) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,843 shares of the pharmacy operator’s stock after selling 236 shares during the period. Waterloo Capital L.P.’s holdings in CVS Health were worth $397,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CVS. Ridgewood Investments LLC increased its holdings in shares of CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 450 shares during the period. Stonebridge Financial Group LLC bought a new position in CVS Health during the 4th quarter worth approximately $28,000. Hopwood Financial Services Inc. acquired a new stake in CVS Health during the 4th quarter worth about $29,000. Legacy Investment Solutions LLC bought a new position in shares of CVS Health during the 3rd quarter worth approximately $31,000. Finally, Financial Perspectives Inc grew its stake in CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator’s stock valued at $36,000 after acquiring an additional 466 shares during the period. 80.66% of the stock is owned by institutional investors.

Insider Activity at CVS Health

In other CVS Health news, Director Michael F. Mahoney acquired 30,000 shares of CVS Health stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is owned by company insiders.

CVS Health Trading Up 0.2 %

Shares of CVS stock opened at $63.79 on Tuesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The stock has a fifty day simple moving average of $63.62 and a two-hundred day simple moving average of $58.05. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $74.85. The firm has a market capitalization of $80.43 billion, a PE ratio of 17.43, a PEG ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 4.17%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s dividend payout ratio (DPR) is currently 72.68%.

Analyst Ratings Changes

Several brokerages have recently commented on CVS. Leerink Partners upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and increased their target price for the company from $55.00 to $75.00 in a report on Thursday, February 13th. StockNews.com upgraded CVS Health from a “sell” rating to a “hold” rating in a research report on Thursday, February 13th. Barclays increased their price objective on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Argus set a $77.00 target price on shares of CVS Health in a research note on Tuesday, February 18th. Finally, Leerink Partnrs upgraded CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.39.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.